Advertisement

The effects of brofaromine, a reversible MAO-A inhibitor, on extracellular serotonin in the raphe nuclei and frontal cortex of freely moving rats

  • P. Celada
  • N. Bel
  • F. Artigas
Conference paper
Part of the Journal of Neural Transmission book series (NEURAL SUPPL, volume 41)

Summary

The effects of brofaromine, a reversible inhibitor of MAO-A, on the extracellular content of serotonin (5-hydroxytryptamine, 5-HT) and 5-hydroxyindoleacetic acid (5-HIAA) have been studied in two regions of the rat brain (midbrain raphe nuclei and frontal cortex). In both areas, locally infused brofaromine induced dose-dependent increases of 5-HT which were more marked in the raphe nuclei. Brofaromine increased extracellular 5-HT more markedly than clorgyline, suggesting that other factors (i.e. inhibition of 5-HT uptake) may be involved in its local effects. Systemic (3 mg/kg, s.c.) brofaromine did not modify extracellular 5-HT in any brain area examined. In contrast, the concurrent administration of brofaromine and deprenyl led to significant changes in the concentration of 5-HT and 5-HIAA in the brain extracellular space. The results are discussed in relation to the role of MAO-A in the control of 5-HT output.

Keywords

Frontal Cortex Raphe Nucleus Serotoninergic Neurone Extracellular Serotonin Extracellular Content 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Adell A, Artigas F (1991) Differential effects of clomipramine given locally or systemi-cally on extracellular 5-hydroxytryptamine in raphe nuclei and frontal cortex. An in vivo microdialysis study. Naunyn-Schmiedebergs Arch Pharmacol 343: 237–244.PubMedGoogle Scholar
  2. Bel N, Artigas F (1993) Fluvoxamine increases preferentially extracellular 5-hydroxytryptamine in the raphe nuclei: an in vivo microdialysis study. Eur J Pharmacol 229: 101–103.CrossRefGoogle Scholar
  3. Blier P, De Montigny C, Chaput Y (1987) Modifications of the serotonin system by antidepressant treatments: implications for the therapeutic response in major depression. J Clin Psychopharmacol 7: 24S–35S.PubMedCrossRefGoogle Scholar
  4. Celada P, Pérez J, Alvarez E, Artigas F (1992) Monoamine oxidase inhibitors phenel-zine and brofaromine increase plasma serotonin and decrease 5-hydroxyindoleacetic acid in major depressive patients. Relationship to clinical improvement. J Clin Psychopharmacol 12: 309–315.PubMedCrossRefGoogle Scholar
  5. Celada P, Artigas F (1993) Monoamine oxidase inhibitors increase preferentially extracellular 5-hydroxytryptamine in the midbrain raphe nuclei. A brain microdialysis study in the awake rat. Naunyn-Schmiedebergs Arch Pharmacol 347: 583–590.PubMedCrossRefGoogle Scholar
  6. Fowler CJ, Tipton KF (1982) Deamination of 5-hydroxytryptamine by both forms of monoamine oxidase in the rat brain. J Neurochem 38: 733–736.PubMedCrossRefGoogle Scholar
  7. Hrdina PD, Foy B, Hepner A, Summers J (1990) Antidepressant binding sites in brain: autoradiographic comparison of [3H]paroxetine and [3H]imipramine localization and relationship to serotonin transporter. J Pharmacol Exp Ther 252: 410–418.PubMedGoogle Scholar
  8. Waldmeier PC, Baumann PA, Delini-Stula A, Bernasconi R, Sigg K, Buech O, Feiner AE (1983) Characterization of a new, short-acting and specific inhibitor of type A monoamine oxidase. Mod Probi Pharmacopsychiatry 19: 31–52.Google Scholar
  9. Waldmeier PC, Stöcklin K (1989) The reversible MAO inhibitor, brofaromine, inhibits serotonin uptake in vivo. Eur J Pharmacol 169: 197–204.PubMedCrossRefGoogle Scholar
  10. Yang HY, Neff NH (1973) β-Phenylethylamine: a specific substrate for type B monoamine oxidase of brain. J Pharmacol Exp Ther 187: 365–371.PubMedGoogle Scholar

Copyright information

© Springer-Verlag 1994

Authors and Affiliations

  • P. Celada
    • 1
  • N. Bel
    • 1
  • F. Artigas
    • 1
  1. 1.Department of NeurochemistryC.I.D., C.S.I.C.BarcelonaSpain

Personalised recommendations